Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID	DTD0280 Transporter Info
Gene Name	SLC31A2
Transporter Name	Probable low affinity copper uptake protein 2
Gene ID	1318
UniProt ID	O15432

Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)
Chemical Compound
DT Modulation1	bathocuproine sulfonate results in decreased abundance of Copper which results in decreased expression of SLC31A2 protein		[3]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	bathocuproine sulfonate results in decreased abundance of Copper which results in decreased expression of SLC31A2 protein which results in increased uptake of and results in increased susceptibility to Cisplatin		[3]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	Copper deficiency results in decreased expression of SLC31A2 protein which results in increased uptake of and results in increased susceptibility to Cisplatin		[3]
Regulation Mechanism			Transcription Factor Info
DT Modulation4	Silver inhibits the reaction SLC31A2 protein results in increased uptake of Copper		[31]
Regulation Mechanism			Transcription Factor Info
DT Modulation5	SLC31A2 protein results in increased abundance of Copper		[30]
Regulation Mechanism			Transcription Factor Info
DT Modulation6	SLC31A2 protein results in increased uptake of Copper		[31]
Regulation Mechanism			Transcription Factor Info
DT Modulation1	Copper Sulfate affects the localization of SLC31A2 protein		[3]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	Copper Sulfate results in decreased degradation of SLC31A2 protein		[3]
Regulation Mechanism			Transcription Factor Info
DT Modulation1	Testosterone co-treated with Calcitriol results in increased expression of SLC31A2 mRNA		[4]
Regulation Mechanism			Transcription Factor Info
DT Modulation1	Testosterone co-treated with Calcitriol results in increased expression of SLC31A2 mRNA		[4]
Regulation Mechanism			Transcription Factor Info
DT Modulation1	bathocuproine sulfonate results in decreased abundance of Copper which results in decreased expression of SLC31A2 protein which results in increased uptake of and results in increased susceptibility to Cisplatin		[3]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	Cisplatin affects the localization of SLC31A2 protein		[3]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	Cisplatin results in decreased degradation of SLC31A2 protein		[3]
Regulation Mechanism			Transcription Factor Info
DT Modulation4	Copper deficiency results in decreased expression of SLC31A2 protein which results in increased uptake of and results in increased susceptibility to Cisplatin		[3]
Regulation Mechanism			Transcription Factor Info
DT Modulation5	SLC31A2 protein affects the susceptibility to Cisplatin		[28]
Regulation Mechanism			Transcription Factor Info
DT Modulation6	SLC31A2 protein affects the uptake of Cisplatin		[29]
Regulation Mechanism			Transcription Factor Info
DT Modulation7	SLC31A2 protein results in decreased susceptibility to Cisplatin		[30]
Regulation Mechanism			Transcription Factor Info
DT Modulation1	NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC31A2 mRNA		[21]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	Valproic Acid affects the expression of SLC31A2 mRNA		[7]
Regulation Mechanism			Transcription Factor Info
DT Modulation1	EGF protein promotes the reaction Estradiol results in decreased expression of SLC31A2 mRNA		[33]
Regulation Mechanism			Transcription Factor Info
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC31A2 mRNA		[21]
Regulation Mechanism			Transcription Factor Info
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of SLC31A2 mRNA		[22]
Regulation Mechanism			Transcription Factor Info
abrine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	abrine results in increased expression of SLC31A2 mRNA		[23]
Regulation Mechanism			Transcription Factor Info
bathocuproine sulfonate	3 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	bathocuproine sulfonate affects the localization of SLC31A2 protein		[3]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	bathocuproine sulfonate results in decreased abundance of Copper which results in decreased expression of SLC31A2 protein		[3]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	bathocuproine sulfonate results in decreased abundance of Copper which results in decreased expression of SLC31A2 protein which results in increased uptake of and results in increased susceptibility to Cisplatin		[3]
Regulation Mechanism			Transcription Factor Info
Cadmium Chloride	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Cadmium Chloride results in increased expression of SLC31A2 mRNA		[26]
Regulation Mechanism			Transcription Factor Info
CGP 52608	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	CGP 52608 promotes the reaction RORA protein binds to SLC31A2 gene		[27]
Regulation Mechanism			Transcription Factor Info
dicrotophos	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	dicrotophos results in decreased expression of SLC31A2 mRNA		[17]
Regulation Mechanism			Transcription Factor Info
di-n-butylphosphoric acid	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	di-n-butylphosphoric acid affects the expression of SLC31A2 mRNA		[32]
Regulation Mechanism			Transcription Factor Info
dorsomorphin	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC31A2 mRNA		[21]
Regulation Mechanism			Transcription Factor Info
Methyl Methanesulfonate	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Methyl Methanesulfonate results in increased expression of SLC31A2 mRNA		[15]
Regulation Mechanism			Transcription Factor Info
monomethylarsonous acid	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	monomethylarsonous acid results in increased expression of SLC31A2 mRNA		[34]
Regulation Mechanism			Transcription Factor Info
Silicon Dioxide	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Silicon Dioxide analog results in increased expression of SLC31A2 mRNA		[36]
Regulation Mechanism			Transcription Factor Info
Silver	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Silver inhibits the reaction SLC31A2 protein results in increased uptake of Copper		[31]
Regulation Mechanism			Transcription Factor Info
sodium arsenite	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	sodium arsenite results in increased abundance of Arsenic which results in increased expression of SLC31A2 mRNA		[25]
Regulation Mechanism			Transcription Factor Info
tetrathiomolybdate	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	SLC31A2 mRNA results in decreased susceptibility to tetrathiomolybdate		[30]
Regulation Mechanism			Transcription Factor Info
triphenyl phosphate	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	triphenyl phosphate affects the expression of SLC31A2 mRNA		[32]
Regulation Mechanism			Transcription Factor Info
zinc chloride	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	zinc chloride results in decreased expression of SLC31A2 mRNA		[1]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	zinc chloride results in increased expression of SLC31A2 mRNA		[1]
Regulation Mechanism			Transcription Factor Info
Nanoparticle
perfluoro-n-nonanoic acid	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	perfluoro-n-nonanoic acid results in decreased expression of SLC31A2 mRNA		[35]
Regulation Mechanism			Transcription Factor Info
Approved Drug
Methotrexate	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Methotrexate increases the expression of SLC31A2		[2]
Copper	7 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Copper inhibits the expression of SLC31A2		[3]
Copper Sulfate	3 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Copper Sulfate increases the expression of SLC31A2		[3]
Calcitriol	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Calcitriol increases the expression of SLC31A2		[4]
Testosterone	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Testosterone increases the expression of SLC31A2		[4]
Zidovudine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Zidovudine increases the expression of SLC31A2		[5]
Dexamethasone	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Dexamethasone inhibits the expression of SLC31A2		[6]
Carbamazepine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Carbamazepine affects the expression of SLC31A2		[7]
Sunitinib	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Sunitinib inhibits the expression of SLC31A2		[8]
Temozolomide	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Temozolomide inhibits the expression of SLC31A2		[9]
Cyclosporine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Cyclosporine inhibits the expression of SLC31A2		[10]
Cisplatin	8 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Cisplatin increases the expression of SLC31A2		[11]
Valproic Acid	3 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Valproic Acid increases the expression of SLC31A2		[12]
Tretinoin	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Tretinoin increases the expression of SLC31A2		[13]
Estradiol	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Estradiol inhibits the expression of SLC31A2		[14]
Drug Marketed but not Approved by US FDA
Zinc chloride	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Zinc chloride inhibits the expression of SLC31A2		[1]
Natural Product
Particulate Matter	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Particulate Matter inhibits the expression of SLC31A2		[18]
Mycotoxins
Aflatoxin B1	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Aflatoxin B1 increases the expression of SLC31A2		[16]
aflatoxin B2	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	aflatoxin B2 results in increased methylation of SLC31A2 intron		[24]
Regulation Mechanism			Transcription Factor Info
Acute Toxic Substance
Formaldehyde	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Formaldehyde increases the expression of SLC31A2		[15]
Paraquat	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Paraquat increases the expression of SLC31A2		[20]
Carcinogen
Ethyl Methanesulfonate	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Ethyl Methanesulfonate increases the expression of SLC31A2		[15]
Benzo(a)pyrene	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Benzo(a)pyrene inhibits the expression of SLC31A2		[19]
Arsenic	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	sodium arsenite results in increased abundance of Arsenic which results in increased expression of SLC31A2 mRNA		[25]
Regulation Mechanism			Transcription Factor Info
Pesticide/Insecticide
Dicrotophos	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Dicrotophos inhibits the expression of SLC31A2		[17]

References
1	Analysis of differential gene-regulatory responses to zinc in human intestinal and placental cell lines. Br J Nutr. 2009 May;101(10):1474-83.
2	Inflammation in methotrexate-induced pulmonary toxicity occurs via the p38 MAPK pathway. Toxicology. 2009 Feb 27;256(3):183-90.
3	Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells. Mol Pharmacol. 2010 Jun;77(6):912-21.
4	Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
5	Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23.
6	Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
7	Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20.
8	Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761.
9	Temozolomide induces activation of Wnt/beta-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278.
10	Integrative "-Omics" Analysis in Primary Human Hepatocytes Unravels Persistent Mechanisms of Cyclosporine A-Induced Cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
11	Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
12	Stem Cell Transcriptome Responses and Corresponding Biomarkers That Indicate the Transition from Adaptive Responses to Cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
13	Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423.
14	17 beta-Estradiol Activates HSF1 via MAPK Signaling in ER alpha-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533.
15	Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
16	Aflatoxin B1 induces persistent epigenomic effects in primary human hepatocytes associated with hepatocellular carcinoma. Toxicology. 2016 Mar 28;350-352:31-9.
17	Molecular mechanisms of discrotophos-induced toxicity in HepG2 cells: The role of CSA in oxidative stress. Food Chem Toxicol. 2017 May;103:253-260.
18	Transcriptional profiling of human bronchial epithelial cell BEAS-2B exposed to diesel and biomass ultrafine particles. BMC Genomics. 2018 Apr 27;19(1):302.
19	Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297.
20	CD34+ derived macrophage and dendritic cells display differential responses to paraquat. Toxicol In Vitro. 2021 Sep;75:105198.
21	Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
22	Benzo[a]pyrene diol epoxide stimulates an inflammatory response in normal human lung fibroblasts through a p53 and JNK mediated pathway. Carcinogenesis. 2010;31(6):1149-57.
23	Integration of transcriptomics, proteomics and metabolomics data to reveal the biological mechanisms of abrin injury in human lung epithelial cells. Toxicol Lett. 2019;312:1-10.
24	Effect of aflatoxin B(1), benzo[a]pyrene, and methapyrilene on transcriptomic and epigenetic alterations in human liver HepaRG cells. Food Chem Toxicol. 2018;121:214-223.
25	Using transcriptomic signatures to elucidate individual and mixture effects of inorganic arsenic and manganese in human placental trophoblast HTR-8/SVneo cells. Toxicol Sci. 2025;203(2):216-226.
26	Evaluation of Cd-induced cytotoxicity in primary human keratinocytes. Hum Exp Toxicol. 2024;43:9603271231224458.
27	Identification of potential target genes of ROR-alpha in THP1 and HUVEC cell lines. Exp Cell Res. 2017;353(1):6-15.
28	Association of copper transporter expression with platinum resistance in epithelial ovarian cancer. Anticancer Res. 2013;33(4):1409-14.
29	Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin. Clin Cancer Res. 2009;15(13):4312-21.
30	Copper transporter 2 regulates intracellular copper and sensitivity to cisplatin. Metallomics. 2014;6(3):654-61.
31	Ctr2 is partially localized to the plasma membrane and stimulates copper uptake in COS-7 cells. Biochem J. 2008;409(3):731-40.
32	Association between Organophosphate Ester Exposure and Insulin Resistance with Glycometabolic Disorders among Older Chinese Adults 60-69 Years of Age: Evidence from the China BAPE Study. Environ Health Perspect. 2023;131(4):47009.
33	Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor alpha signalling and results in tamoxifen insensitive proliferation. BMC Cancer. 2014 Apr 23;14:283.
34	Transcriptional Modulation of the ERK1/2 MAPK and NF-B Pathways in Human Urothelial Cells After Trivalent Arsenical Exposure: Implications for Urinary Bladder Cancer. J Can Res Updates. 2012;1:57-68.
35	Perfluorooctanoic acid (PFOA), perfluorooctane sulfonic acid (PFOS), and perfluorononanoic acid (PFNA) increase triglyceride levels and decrease cholesterogenic gene expression in human HepaRG liver cells. Arch Toxicol. 2020 Sep;94(9):3137-3155.
36	High-throughput, quantitative assessment of the effects of low-dose silica nanoparticles on lung cells: grasping complex toxicity with a great depth of field. BMC Genomics. 2015;16(1):315.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.

Detail Information of Exogenous Modulation

Visitor Map

Correspondence